Open Nav

Cairn Biosciences

  • Mary Ludlam, Cairn Biosciences

Investor exposure for Series A fundraising

  • Date:Thursday, October 18
  • Time:2:00 PM - 2:15 PM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Cairn Biosciences is developing next-generation therapeutics that overcome acquired resistance to cancer therapy. Cairn’s drug discovery engine addresses the profound unmet need for new tools to decipher cellular complexity and enable scalable discovery of groundbreaking therapies. Our approach encompasses cutting-edge advances in microfluidics, synthetic biology-enabled high-throughput screening and induced pluripotent stem cell-based modeling. We industrialize the monitoring of multiple dynamic facets of previously inaccessible biology in live cells, enabling accelerated discovery of a pipeline of drugs for a wide range of indications. Our initial focus is the compelling opportunity to benefit cancer patients by overcoming acquired resistance to PARP inhibitors – a multibillion dollar market. Our vision is a world where killer diseases are relegated to chronic conditions by Cairn’s approach to overcoming disease progression.
  • Company
  • Company HQ City:San Francisco
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Mary Ludlam
  • Year Founded:2013
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :PARP resistance inhibitor
  • Development Phase of Primary Product:Discovery
  • Additional Information/Comments:We are applying for a discovery track presentation
  • Previous and Current Investors:NIH/NSF (non-dilutive SBIR)
  • Size of Last Investment Round:N/A all non-dilutive funds to-date
  • Total Amount Raised to Date, In All Rounds:$7.7M
Mary Ludlam
Cairn Biosciences